Trevena, Inc. to Present at September Virtual Investor Conferences
- H.C. Wainwright: 22nd Annual Global Investment Conference -
September 14th
- Cantor Fitzgerald Virtual Global Healthcare Conference -
September 17th
-Oppenheimer Fall Healthcare Life Sciences & MedTech Summit -
September 23rd
CHESTERBROOK, Pa., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that management will participate in the following conferences in the month of September and invites investors to participate by webcast. Please see additional details below:
H.C. Wainwright: 22nd Annual Global Investment Conference | |
Title: | Trevena (TRVN) Fireside Chat |
Date: | Monday, September 14th, 2020 |
Time: | 2:00 – 2:20 p.m. Eastern Time |
Presenters: | Carrie Bourdow, President & Chief Executive Officer |
Mark Demitrack, M.D., SVP & Chief Medical Officer | |
Cantor Fitzgerald Virtual Global Healthcare Conference | |
Title: | Trevena (TRVN) Fireside Chat |
Date: | Thursday, September 17th, 2020 |
Time: | 2:00 – 2:30 p.m. Eastern Time |
Presenter: | Carrie Bourdow, President & Chief Executive Officer |
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit | |
Title: | Trevena (TRVN) Virtual Presentation |
Date: | Wednesday, September 23rd, 2020 |
Time: | 11:40 a.m. – 12:20 p.m. Eastern Time |
Presenter: | Bob Yoder, SVP & Chief Business Officer |
Webcast Links:
A replay of the webcast will be accessible on the Events page of the Investors section on the Company’s website at https://www.trevena.com/investors/events-presentations/ir-calendar.
About Trevena
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company also has four novel and differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, and TRV027 for acute lung injury / abnormal blood clotting in COVID-19 patients. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating a variety of CNS disorders.